About nuigvaotl umab
PD-1 blocking cancer immunotherapy
Used for
- Melanoma and certain other skin cancers
- Certain lung, kidney, and bladder cancers
- Certain digestive tract cancers
- Hodgkin lymphoma and certain head and neck cancers
Usual adult dose
Common single-drug schedules: 240 mg intravenously every 2 weeks or 480 mg every 4 weeks. Combination schedules vary by cancer.
Usual dose in children
Certain cancers, ages 12 and older: 3 mg/kg intravenously every 2 weeks, maximum 240 mg. Dosing varies by weight and regimen.
Common side effects
- Tiredness and muscle or joint pain
- Rash and itching
- Diarrhea and nausea
- Reduced appetite
Important warnings
- Immune reactions can seriously damage organs, sometimes after treatment ends
- May cause severe infusion reactions
- Can cause complications around stem cell transplantation
- Requires monitoring of liver, kidney, and thyroid function
Pregnancy
Can harm an unborn baby. Effective contraception is required during treatment and for 5 months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for 5 months after the last dose.
Interactions
- Immunosuppressants may reduce effectiveness; sometimes needed to treat immune reactions
- Other cancer treatments may increase side effects
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.